Intellia Q3 earnings: Worst performance as March 2027 decision looms

Intellia Q3 earnings reveal a quiet period as all eyes turn to the crucial March 2027 approval decision.

SSY Group Drug Approvals: Best Way to Invest Smart

SSY Group drug approvals are attracting investor attention. Discover how these developments can impact your investment strategy.